|
1
|
Bilimoria KY, Bentrem DJ, Wayne JD, Ko CY,
Bennett CL and Talamonti MS: Small bowel cancer in the United
States: Changes in epidemiology, treatment, and survival over the
last 20 years. Ann Surg. 249:63–71. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Halfdanarson TR, McWilliams RR, Donohue JH
and Quevedo JF: A single-institution experience with 491 cases of
small bowel adenocarcinoma. Am J Surg. 199:797–803. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Overman MJ, Hu CY, Wolff RA and Chang GJ:
Prognostic value of lymph node evaluation in small bowel
adenocarcinoma: Analysis of the surveillance, epidemiology, and end
results database. Cancer. 116:5374–5382. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Choo R, Pearse M, Danjoux C, et al:
Analysis of gastrointestinal and genitourinary morbidity of
postoperative radiotherapy for pathologic T3 disease or positive
surgical margins after radical prostatectomy using national cancer
institute expanded common toxicity criteria. Int J Radiat Oncol
Biol Phys. 72:989–995. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kautio AL, Haanpää M, Kautiainen H, et al:
Oxaliplatin scale and National Cancer Institute-Common Toxicity
Criteria in the assessment of chemotherapy-induced peripheral
neuropathy. Anticancer Res. 31:3493–3496. 2011.PubMed/NCBI
|
|
6
|
Overman MJ, Hu C-Y, Kopetz S, Abbruzzese
JL, Wolff RA and Chang GJ: A population-based comparison of
adenocarcinoma of the large and small intestine: Insights into a
rare disease. Ann Surg Oncol. 19:1439–1445. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Gibson MK, Holcroft CA, Kvols LK and
Haller D: Phase II study of 5-fluorouracil, doxorubicin, and
mitomycin C for metastatic small bowel adenocarcinoma. Oncologist.
10:132–137. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lu Y, Fröbom R and Lagergren J: Incidence
patterns of small bowel cancer in a population-based study in
Sweden: Increase in duodenal adenocarcinoma. Cancer Epidemiol.
36:e158–e163. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ryder NM, Ko CY, Hines OJ, Gloor B and
Reber HA: Primary duodenal adenocarcinoma: A 40-year experience.
Arch Surg. 135:1070–1075. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Czaykowski P and Hui D: Chemotherapy in
small bowel adenocarcinoma: 10-year experience of the British
Columbia Cancer Agency. Clin Oncol (R Coll Radiol). 19:143–149.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Overman MJ, Varadhachary GR, Kopetz S,
Adinin R, Lin E, Morris JS, Eng C, Abbruzzese JL and Wolff RA:
Phase II study of capecitabine and oxaliplatin for advanced
adenocarcinoma of the small bowel and ampulla of Vater. J Clin
Oncol. 27:2598–2603. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wang X, Wang ML, Zhou LY, Lu XY, Yang JF
and Yu HG: Randomized phase II study comparing paclitaxel with S-1
vs. S-1 as first-line treatment in patients with advanced gastric
cancer. Clin Transl Oncol. 15:836–842. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ajani JA, Rodriguez W, Bodoky G,
Moiseyenko V, Lichinitser M, Gorbunova V, Vynnychenko I, Garin A,
Lang I and Falcon S: Multicenter phase III comparison of
cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced
gastric or gastroesophageal adenocarcinoma study: The FLAGS trial.
J Clin Oncol. 28:1547–1553. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Koizumi W, Narahara H, Hara T, Takagane A,
Akiya T, Takagi M, Miyashita K, Nishizaki T, Kobayashi O, Takiyama
W, et al: S-1 plus cisplatin versus S-1 alone for first-line
treatment of advanced gastric cancer (SPIRITS trial): A phase III
trial. Lancet Oncol. 9:215–221. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Rosati G, Ferrara D and Manzione L: New
perspectives in the treatment of advanced or metastatic gastric
cancer. World J Gastroenterol. 15:2689–2692. 2009. View Article : Google Scholar : PubMed/NCBI
|
